The answer lies on three levels: scientific, epistemological, and practical.
Classical dermatology diagnoses disease through visible morphological elements—macules, papules, plaques, erosions, and similar lesions. However, this approach describes consequences rather than causes. Morphological signs represent only the surface expression of deeper cellular processes, and their external similarity often conceals fundamentally different pathogenetic origins. Consequently, identical symptoms may arise from entirely different cellular mechanisms and require different therapeutic strategies.
Diagnosis depends heavily on the physician’s experience and visual memory. What one specialist identifies as eczema may be interpreted by another as dermatitis and by a third as a mycosis. In the era of digital medicine and precision diagnostics, such a degree of uncertainty is becoming unacceptable.
Traditional dermatology captures a static moment of disease but fails to identify transitions between states—such as inflammation, regeneration, and remission. Yet it is precisely within these transitions that the true physiology and pathology of the skin become apparent.
Contemporary technologies, such as flow cytometry, make it possible to view tissue not as a visible lesion on the skin but as a map of cellular phenotypes and their interactions. Classical dermatology simply lacks the conceptual framework and analytical tools required to interpret such data.
A morphological diagnosis cannot explain why different patients with the same clinical form of disease respond differently to therapy. Only phenotypic analysis of cells can reveal these differences and thereby move dermatology toward individualized treatment.
Phenotypic Dermatology is a scientifically grounded and reproducible concept based on flow-cytometric and cytological analysis of the skin.
An original method—the Skin Cytoimmunogram (SCIG)—has been developed and validated, enabling quantitative assessment of cellular subpopulations and objective characterization of their phenotypes.
It has been demonstrated that the phenotype of a cellular subpopulation, rather than the morphological element of a rash, represents the true unit of measurement of skin condition.
Experimental studies have confirmed the relationship between changes in cellular phenotypes and the clinical manifestations of skin diseases, including atopic dermatitis, psoriasis, wound-healing processes, and others.
Biotechnological products developed on the basis of this theory, such as Cellgel®, have demonstrated the practical feasibility of the phenotypic approach by accelerating regeneration, activating CD34⁺CD45^dim cells, and optimizing tissue repair.
Diagnosis ceases to be descriptive and subjective; it becomes quantitative and based on cellular phenotypes.
Dermatology evolves from a discipline of observation into a science capable of analyzing and predicting skin states.
Diseases with similar external manifestations but different cellular origins can now be distinguished from one another.
Physicians acquire objective instruments for patient stratification and for monitoring therapeutic effectiveness.
For the first time, direct monitoring of cellular processes during treatment and recovery becomes possible.
Creation of an international database of skin-cell phenotypes and a digital “atlas” of skin states as the foundation for standardizing phenotypic analysis.
Integration of Phenotypic Dermatology with single-cell and spatial transcriptomics technologies for spatiotemporal modeling of pathological processes.
Application of artificial intelligence for interpretation of cytoimmunograms and prediction of therapeutic responses.
Development of personalized phenotypic therapy through correction of skin-cell composition according to an individual patient profile.
Creation of next-generation diagnostic and therapeutic platforms integrating laboratory, bioinformatic, and clinical data into a unified phenotypic-analysis system.
Thus, Phenotypic Dermatology brings the era of descriptive skin medicine to a close and opens a new era—one of measurable, controllable, and predictable skin states.
Physicians gain the ability to measure skin condition at the level of cellular populations rather than relying solely on external manifestations.
The Skin Cytoimmunogram enables therapy selection based on an individual phenotypic profile, prediction of treatment effectiveness, and dynamic adjustment of therapeutic strategies.
Changes in cellular phenotypes reflect the direction of disease progression—toward remission or exacerbation—making management of skin conditions possible.
Subjective judgments of “improvement” are replaced by quantitative criteria, including the balance between inflammatory and regenerative subpopulations and indices of phenotypic activity.
Interaction with immunology and cellular biology forms a new field: Phenotypic Skin Medicine.
Development of standardized panels of phenotypic markers for common skin diseases.
Implementation of the Skin Cytoimmunogram in laboratory diagnostics and dermatological practice.
Development of agents designed to modulate skin-cell phenotypes (for example, stimulation of regenerative CD34⁺ cells or suppression of pro-inflammatory Th17/Th22 populations).
Evaluation of cosmetic and regenerative procedures based on phenotypic shifts rather than solely clinical observation.
Dynamic monitoring of skin condition during treatment and aging.
Prediction of risks associated with chronic inflammation and pathological scar formation.
Creation of educational programs devoted to the phenotypic approach for dermatologists, cosmetologists, and researchers.
Development of methodological guidelines for incorporating phenotypic indicators into clinical research.
Integration with modern multi-omics technologies, including spatial transcriptomics, proteomics, and skin metabolomics.
Creation of an international database of skin-cell phenotypes—a digital atlas of normal and pathological states.
Development of artificial-intelligence algorithms for automated interpretation of Skin Cytoimmunograms and prediction of disease outcomes.
Investigation of regenerative phenotypes and development of therapies capable of selectively modifying cellular profiles.
Advancement of the concept of Phenotypic Medicine, in which the skin serves as a model organ for studying cellular interactions throughout the human body.
